BMS 582949

Drug Profile

BMS 582949

Alternative Names: BMS-582949; PS 540446

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; Pharmacopeia Drug Discovery
  • Developer Bristol-Myers Squibb
  • Class Antirheumatics; Benzamides; Skin disorder therapies; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 22 Mar 2011 Discontinued - Phase-II for Atherosclerosis in USA (PO)
  • 22 Mar 2011 Discontinued - Phase-II for Plaque psoriasis in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top